CTOs on the Move

Atmos-Tech Industries

www.atmostech.com

 
Atmos- Tech Industries offers high quality controlled environment and cleanroom products and superior customer service.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

The Bridgeway

The BridgeWay Hospital, located in Central Arkansas, offers an innovative recovery experience at the foothills of the Ouachita Mountains. Here, we offer a continuum of services designed to help children, adolescents, adults and seniors who are experien...

Metro Vein Centers

Metro Vein Centers is a network of trusted vein specialists and vascular surgeons, specializing in varicose veins, spider veins and other venous conditions. Book your appointment online!

South Coast Clinical Trials

South Coast Clinical Trials is a Anaheim, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.

BeyondSpring

BeyondSpring is a Global, Clinical-Stage. Bio-pharmaceutical Company. Developing Innovative Immuno-Oncology Cancer Therapies with a Robust Pipeline from Internal Development and from Collaboration with University of Washington in De Novo Drug Discovery Using a Ubiquitination Platform.